GRAL Stock Chart & Stats
$1325.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1325.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$825.00 - $1,997.99
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
$116.32B
Enterprise Value$2.17B
Total Cash (Recent Filing)$861.61M
Total Debt (Recent Filing)$91.31M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Nov 18, 2026EPS Estimate
-45.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.75
Shares Outstanding44,666,233
10 Day Avg. Volume39
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,031.92Price Target Upside53.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-176.08
Revenue Forecast (FY)$3.31B
Bulls Say, Bears Say
Bulls Say
Revenue And Test Volume GrowthStrong growth in both revenue and test volume indicates expanding adoption of Galleri and improving commercial reach. Continued volume gains can support operating leverage, strengthen provider relationships, and build a larger base of real-world usage over the next several quarters.
Differentiated Clinical EvidenceThe reported clinical profile provides a meaningful basis for differentiation in the MCED market, particularly through low false positives and substantial detection improvements. Evidence across large studies may support regulatory review, physician confidence, and longer-term adoption if execution continues.
Liquidity And Low LeverageSubstantial liquidity and very low leverage provide financial flexibility while GRAIL funds commercialization, clinical work, and regulatory efforts. The Samsung strategic investment also adds partnership support, helping the company pursue expansion without relying primarily on additional debt.
Bears Say
Persistent Losses And Cash BurnGRAIL remains dependent on substantial funding to sustain operations because cash generation is deeply negative and adjusted EBITDA losses are still widening. Persistent burn can reduce financial flexibility over time and may require external financing before the business reaches sustainable profitability.
NHS-Galleri Endpoint MissMissing the primary endpoint is a significant clinical setback even though the study produced positive secondary findings. It may complicate regulatory and reimbursement discussions, require additional evidence or follow-up, and create a more demanding path to broad institutional adoption.
Regulatory Timing UncertaintyUncertainty around the FDA advisory committee and approval timeline can delay the transition from commercial testing to broader regulated access and payer discussions. A later decision would prolong investment needs, defer potential scale benefits, and increase execution risk around the 2027 target.
GRAIL Inc News
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $825.00 and its highest was $1997.99 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $116.32B.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Nov 18, 2026 which is in 43 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Aug 05, 2026. The company reported -$46.324 earnings per share for the quarter, beating the consensus estimate of -$48.061 by $1.737.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Undervalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate is -45.26.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 44,666,233 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$46.324 in its last earnings report, beating expectations of -$48.061. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in MX:GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,031.92 (53.35% Upside)
$2,031.92 (53.35% Upside)
Blogger Sentiment
Bullish
MX:GRAL Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $19.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GRAIL Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.View all MX:GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$2,031.92
▲(53.35% Upside)